おすすめの製品
形状
pellets
保管温度
−20°C
アプリケーション
DNA-encoded library (DEL) technology is a drug discovery tool containing small DNA-barcoded compounds (Satz 2018). The DyNAbind fragment DEL contains small molecular weight compounds. The high ligand efficiency of fragment molecules is harnessed to effectively probe a target′s binding site and increase the likelihood of discovering binders (Murray and Rees 2009, Murray et al. 2012). Moreover, this library uses DyNAbind′s proprietary Dynamic Library technology to drive binder optimization and reveal not only individual fragments, but also joined fragment pairs for over 370,000 highly diverse structures (Reddavide et al. 2015, Reddavide et al. 2019). DyNAbind′s proprietary Dynamic Library technology reshuffles fragment pairs to automatically optimize the affinity of binders and increase the chances of finding good hits. After a pooled screening approach, bound fragments can be determined using next-generation sequencing of the barcodes. Analysis of the sequencing data is provided at no additional cost through a portal on our website which will generate a list of the fragments that bind the target. These fragments can be used as structural starting points to develop larger, more drug-like compounds.
Analysis Portal
More information about DyNAbind
Analysis Portal
More information about DyNAbind
特徴および利点
Product Features and Benefits:
Product Overview:
- Off-the-shelf, affordable access to DEL technology
- Dynamic fragment library provides a revolutionary approach to DELs offering unprecedented library and data quality
- High level quality control with every single member individually purified and validated to maximize data reliability and chances for finding good hits
- Rule of Three used in library design ensures compounds are in favorable fragment space with good ligand efficiency and plenty of room for optimization (Congreve et al. 2003, Jhoti et al. 2013)
- Ability to perform and validate initial DEL screening internally before engaging service provider
- A library with maximized diversity, ready to deploy against nearly any druggable target
Product Overview:
- Dynamic fragment-based DEL as alternative or complement to existing screening technologies
- Consumable, off-the-shelf product for immediate use
- 5 vials, each containing a single-use library for one experimental condition
- Detailed protocol accessible to most drug discovery labs
- A dedicated analysis portal and protocol to identify hits
法的情報
Product of DyNAbind GmbH
The use of this DyNAbind Product (the “Product”) is covered by European Patents EP 3 094 745 B1 and EP 3 169 832 B1 and corresponding applications pending in the US, Canada, and Japan. Purchaser is granted the right to use the Product for its internal research use only. This limited use label license does not grant the purchaser any right to use resulting fragments or products in commercial products or services. For information on commercial rights, please contact the outlicensing department at licensing@dynabind.com.
The use of this DyNAbind Product (the “Product”) is covered by European Patents EP 3 094 745 B1 and EP 3 169 832 B1 and corresponding applications pending in the US, Canada, and Japan. Purchaser is granted the right to use the Product for its internal research use only. This limited use label license does not grant the purchaser any right to use resulting fragments or products in commercial products or services. For information on commercial rights, please contact the outlicensing department at licensing@dynabind.com.
DyNAbind is a registered trademark of DyNAbind GmbH
保管分類コード
13 - Non Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
DYNA001-1EA:
DYNA001-1EA-KC:
最新バージョンのいずれかを選択してください：
この製品を見ている人はこちらもチェック
The 'rule of three' for fragment-based drug discovery: where are we now?
Harren Jhoti et al.
Nature reviews. Drug discovery, 12(8), 644-645 (2013-07-13)
Christopher W Murray et al.
Trends in pharmacological sciences, 33(5), 224-232 (2012-03-31)
Fragment-based drug discovery (FBDD) has become established in both industry and academia as an alternative approach to high-throughput screening for the generation of chemical leads for drug targets. In FBDD, specialised detection methods are used to identify small chemical compounds
Francesco V Reddavide et al.
Angewandte Chemie (International ed. in English), 54(27), 7924-7928 (2015-05-28)
Dynamic combinatorial chemistry (DCC) explores the thermodynamic equilibrium of reversible reactions. Its application in the discovery of protein binders is largely limited by difficulties in the analysis of complex reaction mixtures. DNA-encoded chemical library (DECL) technology allows the selection of
Alexander L Satz
ACS medicinal chemistry letters, 9(5), 408-410 (2018-05-26)
Use of DNA-encoded libraries (DELs) in the pharmaceutical industry has rapidly increased. We discuss what to expect when you run a DEL screen and contemplate guidelines for library design. Additionally, we consider some visionary work and extrapolate to the future.
A 'rule of three' for fragment-based lead discovery?
Miles Congreve et al.
Drug discovery today, 8(19), 876-877 (2003-10-14)
資料
Fragment-Based DNA-Encoded Library for Drug Discovery
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）